Novel VAR2CSA Immunogens and Methods of Use Thereof
Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use
New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins
Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 Coronavirus
Pre-Biotic Formulation of Topical Chemicals for Use on Human Skin
A Wearable Device for Monitoring Pregnancy Health
Summary:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for clinical validation and to further develop the technology.
Description of Technology:
Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for engineered chimeric snoRNA guides that recruit NAT10 to a specific target and cause directed acetylation of the target. They could be used to treat haploinsufficiency-associated disorders or diseases.
Description of Technology:
Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response
The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy could also be used to develop vaccines against cancer or other infectious diseases (ex. SARS-CoV-2).
Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors
Tailoring the best treatments to cancer patients remains a highly important endeavor in the oncology field. However, personalized treatment courses are challenging to determine, and technologies or methods that can successfully be employed for precision oncology are lacking.